Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic mesenchymal stem cells (FRCC FMBA)
- Development stage
- Unknown
- Lead developer
- Federal Research Clinical Center of the Federal Medical and Biological Agency
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Allogeneic mesenchymal stem cells (MSCs) are a cell therapy developed by the Federal Research Clinical Center of the Federal Medical & Biological Agency (FRCC FMBA) in Russia for the treatment of critical limb ischemia (CLI). These adult stem cells are harvested from healthy donors and administered via intramuscular injection into the ischemic limb. The therapeutic rationale is based on the cells' ability to migrate to sites of injury and secrete a variety of paracrine factors, including angiogenic growth factors and anti-inflammatory cytokines. This secretome promotes the formation of new blood vessels (angiogenesis), improves local blood flow, and supports tissue repair in patients who are not candidates for standard surgical or endovascular revascularization.
- Other names
- allogeneic mesenchymal stem cellsmesenchymal stem cells
Beyond the preview
Go deeper on allogeneic mesenchymal stem cells (FRCC FMBA).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic mesenchymal stem cells (FRCC FMBA).